Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient
The present invention provides a composition, such as a food and pharmaceutical agent, which comprises dihomo-γ-linolenic acid, and which has the effect of preventing or treating skin diseases; a composition such as a food and pharmaceutical agent which comprises dihomo-γ-linolenic acid and which has the effect of preventing or treating skin diseases; and a composition which comprises dihomo-γ-linolenic acid and which has the effect of preventing or treating diseases related to increased mast cell count.
1. A method for treating skin inflammation caused by ultraviolet rays or skin damage caused by ultraviolet rays in an individual, consisting essentially of administering dihomo-γ-linolenic acid (DGLA) to the individual in an amount sufficient to treat skin inflammation caused by ultraviolet rays or skin damage caused by ultraviolet rays in the individual, wherein said DGLA is derived from a microorganism, and wherein the amount ingested of is 5 mg-600 mg per day.
2. The method according to claim 1 , wherein the individual is an adult.
3. The method according to claim 1 , wherein the DGLA is in a food or beverage, or a pharmaceutical composition.
4. The method according to claim 3 , wherein said pharmaceutical composition is in the form of a solution, a pill, a tablet or a capsule.
5. The method according to claim 1 , wherein said dihomo-γ-linolenic acid (DGLA) is in the form of a glyceride, a phospholipid, a glycolipid, an alkylester, or a free fatty acid or a salt thereof.
6. The method according to claim 1 , wherein said glyceride is a triglyceride, a diglyceride, or a monoglyceride.
7. The method according to claim 1 , wherein the composition is administered to a subject having a low dihomo-γ-linolenic acid (DGLA) level.
8. The method according to claim 7 , wherein the subject having a low dihomo-γ-linolenic acid (DGLA) level is a subject wherein Δ6 desaturase and/or carbon chain elongase are dysfunctional, insufficient or lacked.
9. The method according to claim 3 , wherein the food or beverage is baby food.
10. The method according to claim 1 , wherein the amount ingested of DGLA is 0.08 mg/kg-3.3 mg/kg body weight of said individual per day.
11. The method according to claim 1 , wherein the amount ingested of DGLA is 0.08 mg/kg-2.5 mg/kg body weight of said individual per day.
12. The method according to claim 1 , wherein the amount ingested of DGLA is 5 mg-200 mg per day,
13. The method according to claim 1 , wherein the amount ingested of DGLA is 5 mg-150 mg per day.